NASDAQ: LYRA - Lyra Therapeutics, Inc.

Rentabilidade por seis meses: -95.6%
Setor: Healthcare

Cronograma de promoção Lyra Therapeutics, Inc.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.

Mais detalhes
The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

Выручка 0.000285
EBITDA -0.0165
Число акций ао 0.0498 млрд
P/S 192.29
P/BV 1.28
EV/EBITDA 0.393
Цена ао 6.13
ISIN US55234L1052
Сайт https://lyratherapeutics.com
Валюта usd
IPO date 2020-05-01
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Alteração de preço por dia: 0% (0.2284)
Alteração de preço por semana: +2.33% (0.2232)
Alteração de preço por mês: -18.43% (0.28)
Alteração de preço em 3 meses: -20.94% (0.2889)
Mudança de preço em seis meses: -95.6% (5.19)
Mudança de preço por ano: -93.55% (3.54)
Mudança de preço em 3 anos: -97.39% (8.74)
Mudança de preço desde o início do ano: -92.58% (3.08)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 159.19 1
P/BV 2.77 6
P/E 0 0
EV/EBITDA -3.87 0
Total: 3.5

Eficiência

Nome Significado Nota
ROA, % -43.96 0
ROE, % -70.1 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.412 10
Total: 10

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 29.83 4
Rentabilidade Ebitda, % 295.45 10
Rentabilidade EPS, % -51.03 0
Total: 6.8
Mais detalhes

Instituições Volume Compartilhar, %
Perceptive Advisors LLC 12757562 21.35
Nantahala Capital Management, LLC 8100436 13.56
Vestal Point Capital, LP 3000000 5.02
Point72 Asset Management, L.P. 3000000 5.02
Citadel Advisors Llc 2861255 4.79
Samsara BioCapital, LLC 2780261 4.65
VR Adviser, LLC 2575593 4.31
Rosalind Advisors, Inc. 1888720 3.16
PURA VIDA INVESTMENTS, LLC 1413242 2.37
Ikarian Capital, LLC 1254384 2.1

ETF Compartilhar, % Rentabilidade para o ano, % Dividendos, %
ProShares Hedge Replication ETF 0.00008 5.9237999659878 1.47892
iShares Micro-Cap ETF 0.00348 34.327031588619 1.54048
iShares Russell 2000 Growth ETF 0.00096 38.042556988 0.6026
ProShares UltraPro Russell2000 0.0003 89.821266282945 1.47873
Vanguard Russell 2000 Growth ETF 0 37.361289927043 0.60264
Vanguard Russell 2000 ETF 0 32.773459189339 1.48801



Supervisor Cargo Pagamento Ano de nascimento
Dr. Harlan W. Waksal M.D. Executive Chairman 210.06k 1953 (71 ano)
Dr. Maria Palasis Ph.D. CEO, President & Director 942.7k 1965 (59 anos)
Dr. Carmichael S. Roberts Jr., Ph.D. Co-Founder N/A 1969 (55 anos)
Mr. Jason Cavalier CFO, Treasurer & Secretary 464.11k 1973 (51 ano)
Mr. Ray Knox Vice President of Operations N/A
Ms. Vineeta Belanger Ph.D. Senior Vice President of Clinical Affairs N/A
Mr. Ronan P. O'Brien J.D. Chief Legal Officer 1973 (51 ano)
Dr. Robert Richard Ph.D. Senior Vice President of Technical Operations 1958 (66 anos)
Dr. Robert Kern M.D. Chief Clinical Advisor
Ms. Gloria Cosgrove Senior Vice President of Quality

Endereço: United States, Watertown. MA, 480 Arsenal Way - abrir no Google Maps, abrir mapas Yandex
Site: https://lyratherapeutics.com